SCHEMBL5286169

SCHEMBL5286169

CC(C)(C)c1ccc(CCC(=O)Nc2ccc(I)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.60
NR1H4 Q96RI1 5/20 0.59
HDAC3 O15379 2/20 0.54
HDAC4 P56524 2/20 0.54
HDAC1 Q13547 2/20 0.54
HDAC7 Q8WUI4 2/20 0.54
HDAC2 Q92769 2/20 0.54
HDAC10 Q969S8 2/20 0.54
HDAC11 Q96DB2 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
HDAC9 Q9UKV0 2/20 0.54
HDAC5 Q9UQL6 2/20 0.54
MLYCD O95822 1/20 0.51
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
CNR1 P21554 1/20 0.50
RAB9A P51151 1/20 0.48
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13676192 0.87 TRPV1 (0.62) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13675963 0.87 TRPV1 (0.62) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13676146 0.87 TRPV1 (0.62) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13675964 0.87 TRPV1 (0.62) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13676000 0.87 TRPV1 (0.62) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13676145 0.86 TRPV1 (0.60) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL13676043 0.85 MAPT (0.71) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL20625313 0.85 MAPT (0.71) TRPV1NR1H4HDAC3HDAC4HDAC1
SCHEMBL5278945 0.84 TRPV1 (0.59) TRPV1NR1H4MAPTHTTRAB9A
SCHEMBL13676188 0.83 TRPV1 (0.65) TRPV1NR1H4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863756-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-12 EP disclosed
US-20060223837-A1 Biaryl derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2006-10-05 US disclosed
WO-2006102645-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223837-A1 Biaryl derived amide modulators of vanilloid VR1 receptor TRPV1, TRPV2, CNR1 TRPV1 1/4885NR1H4 138/4885HDAC3 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.